Developing novel innate immune engagers for cancer
Affivant Sciences GmbH
Incorporated
27.10.2020Headquarters
BaselSupport
While most immuno-oncology (IO) approaches are based on activation of cytotoxic T-cells, Affivant Sciences develops novel bispecific tetravalent monoclonal antibodies which engage cells from the innate immune system (Natural Killer cells, macrophages) referred to as Innate Cell Engagers (ICEs). This overcomes safety limitations of T cell engagers, and is expected to drive responses in T cell deficient tumor types. Affivant's lead asset, AFVT-2101, binds to Folate Receptor alpha, a tumor target that has been clinically validated for ovarian cancer. The ultra high affinity, selective, CD16A engagement of AFVT-2101 overcomes limitations of Fc active, or Fc enhanced antibodies. We are seeking to grow our pipeline with novel assets that offer high potential in combination with AFVT-2101.
News
Venture Leaders Biotech 2023: Captain’s Blog by Navignostics, Mosanna Therapeutics, Limula, and Tandem Therapeutics (venturelab.swiss)
The Venture Leaders Biotech set sail on the Boston roadshow with immersive expert workshops, uniting entrepreneurs and investors in the US market (venturelab.swiss)
Affivant Sciences: The Venture Leader Biotech innovating the use of immune responses to fight cancer (venturelab.swiss)
Venture Leaders Biotech kick off their Boston roadshow at Swiss Biotech Day (venturelab.swiss)
Swiss National Startup Team 2023: 10 biotech innovators are headed to Boston (venturelab.swiss)
